Medical/Pharmaceuticals
Formosa Pharmaceuticals and Adalvo Limited Announce Licensing Agreement for Clobetasol Propionate Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain
TAIPEI, May 28, 2025 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced that the company has entered into an exclusive licensing agreement with Adalvo Limited ("Adalvo") in the European and Brazilian markets for exclusive rights to the commercialization of clobeta...
2025-05-28 20:00
1782
CARsgen's Satri-cel Granted Priority Review by the NMPA
SHANGHAI, May 28, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the Center for Drug Evaluation (CDE) ofChina's National Medical Products Administration (NMPA) has granted Priority R...
2025-05-28 12:10
1940
Terumo Interventional Systems Announces Commercial Availability of Its ROADSAVER™ Carotid Stent System
– Innovative, dual-layer micromesh, closed-cell stent with the flexibility of an open-cell stent for maximizing clinical outcomes in carotid artery stenting procedures – SOMERSET, N.J., May 27, 2025 /PRNewswire/ -- Terumo Interventional Systems (TIS), a division of Terumo Corporation, is please...
2025-05-28 01:40
2020
Alma Unveils Alma IQ at Eighth Global Alma Academy in Dubrovnik
The next-generation skin analysis platform, set to redefine the aesthetic
consultation experience
CAESAREA, Israel, May 27, 2025 /PRNewswire/ -- Alma
2025-05-27 13:00
2076
ZYLOX Unicorn™ Vascular Closure Device Receives Regulatory Approval in Indonesia
HANGZHOU, China, May 26, 2025 /PRNewswire/ -- Zylox-Tonbridge Medical Technology Co., Ltd. ("Zylox-Tonbridge" or the "Company") today announced that its proprietary ZYLOX Unicorn™ Vascular Closure Device (VCD) has received regulatory approval inIndonesia. This marks the ZYLOX Unicorn™ Vascular Cl...
2025-05-27 10:14
1725
SeekInCare: New Multi-Omics Blood Test Shows Promise for Early Cancer Detection Across Multiple Cancer Types
SAN DIEGO, May 26, 2025 /PRNewswire/ -- A groundbreaking study published in the Journal of Molecular Diagnostics reports the successful clinical validation of SeekInCare®, a novel, non-invasive multi-omics blood test designed for the early detection of multiple cancer types. Developed by research...
2025-05-26 23:00
2317
Lunit Highlights AI's Role in Advancing Precision Oncology at ASCO 2025 with 12 Studies
SEOUL, South Korea, May 26, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, today announced that 12 studies featuring its AI-powered digital pathology solution will be presented at the 2025 American Society of Clinical Oncology (ASCO) ...
2025-05-26 21:00
2117
MGI Tech Showcases Comprehensive Multi-Omics Solutions at ESHG 2025 Milan
MILAN, May 26, 2025 /PRNewswire/ -- MGI Tech Co., Ltd. (MGI), a company dedicated to developing core tools and technologies that drive innovation in life sciences, unveiled cutting-edge multi-omics technologies at the European Society of Human Genetics (ESHG) 2025 conference inMilan. At Booth #31...
2025-05-26 18:30
1780
Dizal to Highlight its Portfolio Advances in Hematologic Malignancies and Lung Cancer at ASCO 2025
* DZD8586 demonstrated significant anti-tumor efficacy in heavily pretreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients with ORR of 84.2% * DZD6008, a BBB-penetrant 4th generation EGFR TKI, showed encouraging and durable anti-tumor activity with favorable safet...
2025-05-26 18:06
2100
VUNO Showcases DeepCARS® at AACN NTI 2025, Highlighting AI-Driven Cardiac Arrest Risk Prediction
– Company engages U.S. critical care professionals with data-driven early warning solution MARLBOROUGH, Mass., May 26, 2025 /PRNewswire/ -- VUNO, a global medical AI company, presented its flagship solution VUNO Med®–DeepCARS® at the 2025 National Teaching Institute & Critical Care Exposition (N...
2025-05-26 13:50
2097
World's First -- XellSmart's Allogeneic iPSC-derived Regenerative Cell Therapy for Spinal Cord Injury Officially Approved by the U.S. FDA for a Registrational Phase I Clinical Trial
SUZHOU, China, May 25, 2025 /PRNewswire/ -- In May 2025, XellSmart Biopharmaceutical (Suzhou/Shanghai) Co., Ltd. officially announced that XellSmart-developed off-the-shelf allogeneic iPSC-derived subtype-specific neural regenerative cell therapy has received official approval from bothChina's N...
2025-05-26 09:00
2180
Celltrion's YUFLYMA® (adalimumab-aaty) receives FDA interchangeability designation for all its approved dosage forms and strengths
* YUFLYMA® (adalimumab-aaty) is a high-concentration (100mg/mL) and citrate-free formulation of Humira® (adalimumab) biosimilar[1] * Celltrion previously received interchangeability (IC) designation for YUFLYMA® (adalimumab-aaty) in prefilled syringes (20mg & 80mg); Expanded interchangeabilit...
2025-05-24 01:47
4303
/DISREGARD RELEASE: Celltrion/
We are advised by Celltrion that journalists and other readers should disregard the news release, Celltrion's YUFLYMA® (adalimumab-aaty) receives FDA interchangeability designation for all its approved dosage forms and strengths, issued21-May-2025 over PR Newswire. ...
2025-05-24 00:01
4184
Mabwell Announces Clinical Data of Multiple ADCs to be presented at 2025 ASCO Annual Meeting
SHANGHAI, May 23, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced multiple clinical research results to be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, including phase Ib/II clini...
2025-05-23 22:00
4216
41st WHO Sasakawa Health Prize Awarded to Denmark's Dr. Merete Nordentoft For Work on Suicide Prevention in Young People
TOKYO, May 23, 2025 /PRNewswire/ -- The 41st WHO Sasakawa Health Prize was
presented to Danish psychiatrist Dr.Merete Nordentoft in recognition of her
work on suicide prevention in young people, during a ceremony at the 78th World
Health Assembly inGeneva on May 23.
2025-05-23 21:00
4264
UniXell Biotechnology announces the first patient dosed with UX-DA001, an investigational autologous iPSC based cell therapy for the treatment of Parkinson's disease, in its Phase 1 study
SHANGHAI, May 23, 2025 /PRNewswire/ -- Shanghai UniXell Biotechnology Co., Ltd. (UniXell Biotech), a biotech company dedicated to innovative cell therapies, announced the successful first administration of its proprietary Parkinson's disease cell drug UX-DA001 inChina in March 2025. The Phase I c...
2025-05-23 19:18
4777
Nona Biosciences Collaboration Partner Pfizer Announces Presentation of Phase 1 Clinical Study Design on MesoC2, an MSLN-Targeting ADC, at the 2025 ASCO Annual Meeting
CAMBRIDGE, Mass., May 23, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to I TM), today announced that its collaborator, Pfizer, will present an abstract detailing the first-in-human Phase 1 clinical study design of MesoC...
2025-05-23 12:21
3249
FDA Clearance of Investigational New Drug Application Received for Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418
Phase 1/2 first-in-human clinical study planned this year SHANGHAI and SAN DIEGO, May 22, 2025 /PRNewswire/ -- Duality Biotherapeutics ("DualityBio", HKEX:09606) partner Avenzo Therapeutics, Inc. ("Avenzo"), a clinical-stage biotechnology company developing next-generation oncology therapies, to...
2025-05-23 10:44
2233
CARsgen's Satri-cel Abstract Available on ASCO Website
SHANGHAI, May 22, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that an abstract of the research results of the confirmatory Phase II clinical trial of satricabtagene autoleucel ("satri-...
2025-05-23 08:00
2152
Eisai to Present E7386, Co-created by PRISM BioLab and Eisai, at the ASCO (American Society of Clinical Oncology) Annual Meeting
Abstract Released for E7386, Co-Developed Through Collaborative Research Between Eisai and PRISM TOKYO, May 22, 2025 /PRNewswire/ -- PRISM BioLab, Co. Ltd. ("PRISM"), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI...
2025-05-23 08:00
3305
Week's Top Stories
Most Reposted
One Universal Production Group (OUP) Officially Opens, Reinforcing Its Position as Asia's Leading IP Ecosystem and Tourism Company
[Picked up by 314 media titles]
2025-12-20 09:36
Singapore Airshow 2026 Marks 10th Edition with New Frontiers in Aviation and Space
[Picked up by 309 media titles]
2025-12-18 19:41
Nine Years of Impact: JULO Disburses USD 1.7 Billion in Digital Financing Across Indonesia
[Picked up by 297 media titles]
2025-12-23 14:23
foodpanda Strengthens Merchant Care with Record Onboarding Milestone in Asia
[Picked up by 292 media titles]
2025-12-18 17:15Rosewood Hotel Group Accelerates Global Expansion with On-Track 2025 Openings; Entering New Sector with Its First-Ever Ski Resort
[Picked up by 289 media titles]
2025-12-19 14:40
Most Read
Cognizant and Microsoft Expand Partnership to Advance AI Transformation and Frontier Firm Experiences
2025-12-18 22:00
6788
Tokyo Lifestyle Co., Ltd. Reports First Six Months of Fiscal Year 2026 Financial Results
2025-12-20 05:05
6090